Abstract: resources into the other five areas where we think we can give the most value mid-term to shareholders and patients."But Morgan Sheng, vice president of Neuroscience at Genentech, is optimistic that new neuroscience therapeutics are on the horizon."I don't see a mass exodus of big pharma and biotech out of neuroscience.Quite the opposite, the field is becoming increasingly competitive, especially in neurodegenerative disorders, multiple sclerosis, pain and rare diseases of the nervous system," he says.Genetic analyses in particular are helping to identify the molecular underpinnings of neural diseases and are pointing to new CNS targets in these indications, he adds (see page 88).Recent deal-making activity bolsters Sheng's position.Takeda Pharmaceuticals partnered